Author
Andreas Bollmann
Other affiliations: Lund University, UCLA Medical Center, Good Samaritan Hospital ...read more
Bio: Andreas Bollmann is an academic researcher from Leipzig University. The author has contributed to research in topics: Atrial fibrillation & Catheter ablation. The author has an hindex of 40, co-authored 343 publications receiving 6214 citations. Previous affiliations of Andreas Bollmann include Lund University & UCLA Medical Center.
Papers published on a yearly basis
Papers
More filters
TL;DR: Application of this limited individualized approach for catheter ablation of atrial fibrillation based on low-voltage areas in the left atrium may have the potential to compensate for the impaired 12-month outcome of patients with endocardial structural defects.
Abstract: Background—Reduced electrogram amplitude has been shown to correlate with diseased myocardium. We describe a novel individualized approach for catheter ablation of atrial fibrillation (AF) based on...
414 citations
TL;DR: Several ECG applications are reviewed where PCA techniques have been successfully employed, including data compression, ST-T segment analysis for the detection of myocardial ischemia and abnormalities in ventricular repolarization, extraction of atrial fibrillatory waves for detailed characterization of atrium fibrillation, and analysis of body surface potential maps.
Abstract: This paper reviews the current status of principal component analysis in the area of ECG signal processing. The fundamentals of PCA are briefly described and the relationship between PCA and Karhunen-Loeve transform is explained. Aspects on PCA related to data with temporal and spatial correlations are considered as adaptive estimation of principal components is. Several ECG applications are reviewed where PCA techniques have been successfully employed, including data compression, ST-T segment analysis for the detection of myocardial ischemia and abnormalities in ventricular repolarization, extraction of atrial fibrillatory waves for detailed characterization of atrial fibrillation, and analysis of body surface potential maps.
322 citations
TL;DR: Although the short-term success rates after VT ablation in NIDCM and ICM patients were similar, the long-term outcomes in NIDsCM patients were significantly worse and the hazard ratio for VT recurrence was significantly higher for NID CM.
Abstract: Background—Data on the outcomes of ventricular tachycardia (VT) ablation in nonischemic dilated cardiomyopathy (NIDCM) are insufficient The Heart Center of Leipzig VT (HELP-VT) study was conducted prospectively to compare outcomes after radiofrequency catheter ablation of VT in patients with NIDCM compared with ischemic cardiomyopathy (ICM) Methods and Results—Two hundred twenty-seven patients, 63 with NIDCM and 164 with ICM, presenting with sustained VT were ablated with radiofrequency catheter ablation Noninducibility of any clinical and nonclinical VT was achieved in 667% of NIDCM and in 774% of ICM patients Ablation of the clinical VT only was achieved in 183% of ICM and in 222% of NIDCM patients There was no statistically significant difference in short-term outcomes between the 2 groups At the 1-year follow-up, VT-free survival in NIDCM was 405% compared with 57% in ICM In univariate analysis, the hazard ratio for VT recurrence was significantly higher for NIDCM (162; 95% confidence int
316 citations
TL;DR: Technical aspects of novel electrocardiogram (ECG) analysis techniques are described and research and clinical applications of these methods for characterization of both the fibrillatory process and the ventricular response during AF are presented.
Abstract: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Neither the natural history of AF nor its response to therapy is sufficiently predictable by clinical and echocardiographic parameters. The purpose of this article is to describe technical aspects of novel electrocardiogram (ECG) analysis techniques and to present research and clinical applications of these methods for characterization of both the fibrillatory process and the ventricular response during AF. Atrial fibrillatory frequency (or rate) can reliably be assessed from the surface ECG using digital signal processing (extraction of atrial signals and spectral analysis). This measurement shows large inter-individual variability and correlates well with intra-atrial cycle length, a parameter which appears to have primary importance in AF maintenance and response to therapy. AF with a low fibrillatory rate is more likely to terminate spontaneously and responds better to antiarrhythmic drugs or cardioversion, whereas high-rate AF is more often persistent and refractory to therapy. Ventricular responses during AF can be characterized by a variety of methods, which include analysis of heart rate variability, RR-interval histograms, Lorenz plots, and non-linear dynamics. These methods have all shown a certain degree of usefulness, either in scientific explorations of atrioventricular (AV) nodal function or in selected clinical questions such as predicting response to drugs, cardioversion, or AV nodal modification. The role of the autonomic nervous system for AF sustenance and termination, as well as for ventricular rate responses, can be explored by different ECG analysis methods. In conclusion, non-invasive characterization of atrial fibrillatory activity and ventricular response can be performed from the surface ECG in AF patients. Different signal processing techniques have been suggested for identification of underlying AF pathomechanisms and prediction of therapy efficacy.
215 citations
TL;DR: Polymorphisms on chromosome 4q25 modulate the risk for AF recurrence after catheter ablation, pointing to a potential role for stratification of AF ablation therapy or peri-interventional management by genotype.
205 citations
Cited by
More filters
Journal Article•
28,685 citations
TL;DR: This document summarizes current research, plans, and recommendations for future research, as well as providing a history of the field and some of the techniques used, currently in use, at the National Institutes of Health.
Abstract: Jeffrey L. Anderson, MD, FACC, FAHA, Chair
Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect
Nancy M. Albert, PhD, RN, FAHA
Biykem Bozkurt, MD, PhD, FACC, FAHA
Ralph G. Brindis, MD, MPH, MACC
Mark A. Creager, MD, FACC, FAHA[#][1]
Lesley H. Curtis, PhD, FAHA
David DeMets, PhD[#][1]
Robert A
6,967 citations
TL;DR: The Task Force for the management of atrial fibrillation of the European Society of Cardiology has been endorsed by the European Stroke Organisation (ESO).
Abstract: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)
Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
Endorsed by the European Stroke Organisation (ESO)
5,255 citations
4,960 citations
Leipzig University1, University of Belgrade2, Leiden University3, Uppsala University4, University of Modena and Reggio Emilia5, University of Barcelona6, Carol Davila University of Medicine and Pharmacy7, National and Kapodistrian University of Athens8, François Rabelais University9, University of Melbourne10, Royal Melbourne Hospital11, University of Lisbon12, University of Birmingham13, University of Groningen14, University Medical Center Groningen15, University of Central Lancashire16
TL;DR: The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only and no commercial use is authorized.
Abstract: Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight <60 kg, concomitant use of dronedarone, erythromycin, ciclosporine or ketokonazole"instead of "Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15mg once daily, if any of the following: creatinine clearance of 30-50 mL/min, body weight <60 kg, concomitant us of verapamil or quinidine or dronedarone."
4,285 citations